Cellular Stress Response and Immune Signaling in Retinal Ischemia–Reperfusion Injury by Gillipsie Minhas et al.
October 2016 | Volume 7 | Article 4441
Review
published: 24 October 2016
doi: 10.3389/fimmu.2016.00444
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Kai Fang, 
University of California 
Los Angeles, USA
Reviewed by: 
M. Heather West Greenlee, 
Iowa State University, USA  
Claudio Bucolo, 
University of Catania, Italy
*Correspondence:
Nooruddin Khan  
noor@uohyd.ac.in
Specialty section: 
This article was submitted to 
Inflammation, 






Minhas G, Sharma J and Khan N 
(2016) Cellular Stress Response 
and Immune Signaling in Retinal 
Ischemia–Reperfusion Injury. 
Front. Immunol. 7:444. 
doi: 10.3389/fimmu.2016.00444
Cellular Stress Response and 
immune Signaling in Retinal 
ischemia–Reperfusion injury
Gillipsie Minhas, Jyoti Sharma and Nooruddin Khan*
Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
Ischemia–reperfusion injury is a well-known pathological hallmark associated with dia-
betic retinopathy, glaucoma, and other related retinopathies that ultimately can lead to 
visual impairment and vision loss. Retinal ischemia pathogenesis involves a cascade of 
detrimental events that include energy failure, excitotoxic damage, calcium imbalance, 
oxidative stress, and eventually cell death. Retina for a long time has been known to 
be an immune privileged site; however, recent investigations reveal that retina, as well 
as the central nervous system, elicits immunological responses during various stress 
cues. Stress condition, such as reperfusion of blood supply post-ischemia results in 
the sequestration of different immune cells, inflammatory mediators including cytokines, 
chemokines, etc., to the ischemic region, which in turn facilitates induction of inflam-
matory conditions in these tissues. The immunological activation during injury or stress 
per  se is beneficial for repair and maintenance of cellular homeostasis, but whether 
the associated inflammation is good or bad, during ischemia–reperfusion injury, hitherto 
remains to be explored. Keeping all these notions in mind, the current review tries to 
address the immune response and host stress response mechanisms involved in isch-
emia–reperfusion injury with the focus on the retina.
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iNTRODUCTiON
Retinal ischemia is a condition that has been found to be connected to a large number of retinal 
diseases such as glaucoma, diabetic retinopathy, and central retinal artery occlusion, which are 
a leading cause of visual impairment or blindness (1–3). Ischemia, in general, is a condition 
that occurs due to disruption in blood supply to a particular tissue or organ, which cuts the 
Abbreviations: ATF6, activating transcription factor 6; BBB, blood–brain barrier; BRB, blood–retina barrier; CCL2, C–C 
motif chemokine ligand 2; CD, cluster of differentiation; CHOP, CCAAT-enhancer-binding protein homologous protein; CNS, 
central nervous system; DAMP, damage-associated molecular pattern; DEREG, depletion of regulatory T cell; eIF2α, eukaryotic 
initiation factor; ER, endoplasmic reticulum; GCN2, general control non-derepressible 2; GFAP, glial fibrillary acidic protein; 
GRP78, 78 kDa glucose-regulated protein; HMGB1, high-mobility group box 1; HRI, heme-regulated inhibitor kinase; ICAM-
1, intracellular adhesion molecule 1; IFNγ, interferon gamma; IL1β, interleukin 1beta; IL18, interleukin 18; IOP, intraocular 
pressure; IRE1, inositol-requiring enzyme 1; ISR, integrated stress response; LC3, microtubule-associated protein light chain 
3; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinases; MCAO, middle cerebral artery occlusion; mRNA, 
messenger ribonucleic acid; NLR, NOD-like receptor; NOD, nucleotide oligomerization domain; PAMP, pathogen-associated 
molecular pattern; PERK, protein kinase RNA-like endoplasmic reticulum kinase; PI3K, phosphatidylinositol-3-kinase; PKR, 
protein kinase RNA-activated; PRR, pattern-recognition receptor; RBPs, RNA-binding proteins; RGCs, retinal ganglion cells; 
ROS, reactive oxygen species; RPE, retinal pigment epithelium; SCID, severe combined immunodeficiency; TCR, T-cell recep-
tor; TGFβ2, transforming growth factor 2; TLR, toll-like receptor; TNF-α, tumor necrosis factor-alpha; TNFR, tumor necrosis 
factor receptor; UPR, unfolded protein response; VEGF, vascular endothelial growth factor.
FiGURe 1 | Multi-faceted cellular responses during retinal ischemia–
reperfusion injury. Different aspects of immune signaling and host 
responses associated with ischemia–reperfusion injury in retina.
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supply of oxygen and glucose, triggering a cascade of events 
that ultimately ends with cell death. Retina being highly meta-
bolic has very high oxygen consumption in the body (4). It  is 
 sensitive to oxygen deficiency, thus making it more susceptible 
to ischemic injury. Retina being an extension of central nervous 
system (CNS), it makes retina an ideal model system not only to 
examine the pathophysiology behind ischemia/hypoxia but also 
to assess different therapeutic strategies in animal models before 
proceeding to clinical trials, which can also be extrapolated to 
the brain (5, 6).
Ischemic cascade consists of energy failure, calcium influx fol-
lowed by depolarization, and oxidative stress (7). Inflammation 
is an important phenomenon in the progression of any injury 
including ischemic injury (8). It usually helps in repair mecha-
nism, but chronic inflammation causes more damage than good, 
triggering the release of reactive oxygen species (ROS), and tissue 
destruction (9). In ischemia–reperfusion injury, a similar condi-
tion is observed during the reperfusion, which is the restoration 
of blood supply to the ischemic tissue. The reoxygenation of tissue 
after ischemia causes more destruction by the production of ROS 
that damage the biomolecules by activation of inflammatory 
responses (10). In the current review, we have focused on the 
immune processes observed during ischemia–reperfusion injury, 
especially in the retina.
ReTiNA: iMMUNe PRiviLeGeD SiTe
For a long time, retina and CNS have been considered as an 
immune privileged site due to its inability to post an immune 
response. The immune cells, which play the usual function of 
processing and presenting the antigens in the periphery, to our 
knowledge have not been reported in the retinal or CNS tissues; 
as a result, CNS is unable to mount an adaptive immune response 
(11). Investigations have also shown the presence of elevated 
levels of anti-inflammatory cytokines, which makes the natural 
environment in the brain as anti-inflammatory (12). Eye also has 
its similar mechanisms to control immune activation, and it con-
tains many factors in aqueous humor that have shown to decrease 
the IFNγ production through the presence of anti-inflammatory 
factors (e.g., TGFβ2), which has demonstrated to reduce TCR 
activation (13–15).
The blood–brain barrier (BBB) provides anatomical and 
physiological protection to CNS. It restricts the migration of 
T lymphocytes and other immune mediators to brain through 
tight junctions between endothelial cells and helps in the main-
tenance of CNS as a unique immune privileged site (16,  17). 
On the similar lines, blood–retina barrier (BRB) is known to 
maintain homeostasis in the retina, which is essential for main-
tenance of immune privilege in the eye (18). The structure of 
BRB allows sustaining this condition in the eye. It is composed 
of two layers of tight junctions: the inner junction is present 
between retinal capillary endothelial cells and the outer one is 
between the RPE (18, 19). Many factors have been studied which 
affect the permeability of BRB, such as oxidative stress, VEGF, 
and inflammation (20, 21).
Recent studies have shown that the CNS tissues have 
specific immune responses against different kinds of trauma, 
infection, or injury, and the term “immune privilege” has 
become implicit (22). All the abovementioned factors and 
barriers make the CNS and retinal tissue isolated from the 
immune response; however, still, these components interact 
with the peripheral immune system (15, 23). Figure 1 enlists 
different aspects of cellular and immune response associated 
with retinal ischemia–reperfusion injury, which have been 
explored through this review.
iSCHeMiA–RePeRFUSiON: STeRiLe 
iNFLAMMATiON
Inflammation is a crucial component of host immune response 
essential for defense against invading pathogens, and it involves 
activation of different immune cells and the release of cytokines, 
chemokines, and other effector molecules. However, there are 
injuries which do not include any pathogen invasion but still 
invoke an inflammatory response, such as ischemia and trauma; 
these are identified as sterile inflammation (24).
In the case of the microbe-induced inflammation, it is 
activated through pattern-recognition receptors (PRRs), 
and these receptors recognize different pathogen-associated 
molecular patterns (PAMPs), such as lipopolysaccharide (LPS), 
dsRNA, toxins, and other foreign molecules. In contrast, sterile 
inflammation involves damage-associated molecular patterns 
(DAMPs) (24). The DAMPs operate in the same way as the 
PAMPs but are endogenous instead of being pathogen derived. 
DAMPs are released by necrotic or apoptotic cells during 
injury and include proteins such as high-mobility group box-1 
(HMGB1), mitochondrial components, uric acid, and others 
(25). Both PAMPs and DAMPs act through toll-like recep-
tors (TLRs), NOD-like receptors (NLRs), and C-type lectin 
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receptors, which are the common PRRs that are present on 
immune cells (26).
TOLL-LiKe ReCePTOR SiGNALiNG
Toll signaling is a pathway that is known to be activated in 
response to many diseases such as ischemia. This pathway was 
first identified in Drosophila, where it is essential for embryonic 
development (27–29). Subsequent studies demonstrated its pres-
ence in mammals (30, 31). TLRs are evolutionarily conserved 
membrane proteins with leucine-rich repeats and extracellular 
ligand-binding domains that recognize the PAMPs and DAMPs 
(32). TLR4 was the first component to be identified in mammals, 
which showed activation by bacterial components. These bacte-
rial cell wall components upon binding to TLR activate the release 
of cytokines that assist in clearance of microbes, but in the case 
of excessive activation, it can become detrimental to host cells 
(33). Although it is now well established that TLR activation is 
associated with pathogen invasion, TLR has also been shown to 
be activated by DAMPs released by cells under stress. One such 
molecule is HMGB1, which is released by necrotic or apoptotic 
cells (34). Activation of TLR signaling, in turn, stimulates NFκB, a 
transcription factor that regulates the expression of genes respon-
sible for cell adhesion, innate immune response, and inflammation 
(35, 36). Figure 2 shows the activation of TLR upon stimulation 
by DAMPs and downstream signaling pathways in response to 
ischemia–reperfusion, which through p38/MAPK signaling and 
NFκB leads to expression of inflammatory cytokines and activa-
tion of inflammasomes (37).
Studies from different animal models have shown the 
important role of TLR signaling in ischemia–reperfusion injury 
(38–42). Hua et al. investigated TLR signaling in global cerebral 
ischemia and revealed neuronal death and increased expression 
of proinflammatory cytokines in wild-type mice subjected to 
ischemic injury. In the absence of TLR4, less infarct volumes 
with reduced cell death were observed in the cerebral ischemia 
mouse model, which demonstrates the deleterious role for TLR 
in ischemia–reperfusion injury (41). Lehnardt et  al. showed 
similar outcome with TLR2-deficient mice, which developed 
less injury as compared to wild-type subjected to middle cerebral 
artery occlusion (MCAO) (43). More studies done to delineate 
the mechanism behind the protective role of TLR deletion have 
shown the contribution of PI3K/Akt pathway, which is already 
known to prevent apoptosis (44, 45). The outcomes observed 
in the brain were also reflected in retinal ischemia–reperfusion 
injury. Qi et  al. generated retinal ischemia injury in rats by 
clamping retinal arteries and demonstrated the TLR4 activation 
post-injury (46). Studies have shown that TLR4-deficient mice 
are neuroprotective in ischemia–reperfusion (47). Kilic et  al. 
exhibited less ischemic damage post-ischemia in focal cerebral 
ischemia as well as retinal ganglion cells (RGCs) degeneration 
in a TLR4 knock-out model (48). He et  al. also demonstrated 
attenuation in neovascularization in retina along with less 
microglial activation and proinflammatory cytokines levels in 
TLR4-deficient mice subjected to ischemia (49). These studies 
emphasize the TLRs as prospective therapeutic targets to regulate 
ischemia–reperfusion injury.
ACTivATiON OF iNFLAMMASOMeS
Inflammasomes are the component of innate immune response, 
which have been implicated in different metabolic and neurode-
generative diseases. Inflammasomes are intracellular, multimeric 
protein complexes that are formed post-detection of PAMPs or 
DAMPs by specific PRRs. Inflammasome activation stimulates the 
expression of IL1β, IL18, and other proinflammatory cytokines 
downstream to initiate the cascade through caspase 1 (50, 51). 
Mechanistically, inflammasomes recruit pro-caspase 1, which 
further oligomerizes and auto-cleaves to form active caspase 1 
that cleaves the pro-forms of cytokines IL1β and IL18 into their 
active forms (52).
The inflammasomes are generally named based on the scaffold 
protein that is associated with it. The most common being the 
NLRs, which also belong to the family of PRRs and are analogous 
to TLRs (53). The best-investigated inflammasomes that have 
been found to be associated with neuroinflammation are NACHT 
domain-LRR domain and pyrin domain containing protein 
(NALP) and nucleotide-binding oligomerization domain-like 
receptor with pyrin domain protein (NLRP1 and 3) (54, 55). The 
activation of NLRP inflammasomes through TLR4 activation 
has been demonstrated in a retinal ischemia–reperfusion injury 
model induced by ligation of retinal blood vessels in rat (46). 
Chi et  al. also investigated the role of inflammasomes in RGC 
death due to retinal ischemia–reperfusion injury in a caspase 
1-independent pathway. The study revealed that the ischemic 
injury increases the levels of TLR4, which further stimulates IL1β 
production through caspase 8 pathway (56). These revelations 
make the inflammasome activation a probable therapeutic for 
retinal ischemic injuries that will help to regulate inflammatory 
responses. It has been demonstrated in an Nlrp3 knock-out mice 
that the absence of inflammasomes delayed the progression of 
CNS injury (57).
ACTivATiON OF  
MiCROGLiA–MACROPHAGeS
Microglia and astrocytes are the resident immune cells present 
in CNS. These are the first line of defense against any injury or 
infection in the CNS. The role of microglia and macrophages 
is controversial with different studies supporting the impact of 
their activation after the injury (58–60). Studies have shown 
that the activation of these cells can either be beneficial or 
detrimental for a tissue. As is seen in the case of Alzheimer’s, 
where the activation of microglia helps in clearance of amyloid 
load and hence is beneficial (61, 62). Similarly, activated mac-
rophages assist in removal of leukocytes through phagocytosis 
(63). In retina, Müller glia are the principal glial cells. Müller 
glia are the radial glia, which are found throughout the thick-
ness of the retina and are associated with a majority of retinal 
degenerations. In normal physiology, Müller glia maintain the 
layer arrangement in the retina, provide trophic support, and 
remove the waste, whereas under the pathological conditions, 
these cells undergo reactive gliosis. The involvement of Müller 
glia in ischemic injury has been implicated through different 
animal models, and it has been shown to play protective as well 
FiGURe 2 | Toll-like receptor signaling during ischemia–reperfusion injury. Specific receptors, such as TLRs, are activated during ischemia–reperfusion 
through damage-associated molecular patterns (DAMPs), which activate downstream MAPK pathway and via different transcription factors such as NFκB and 
c-fos-c-jun, and translate different cell adhesion and inflammatory molecules, which causes inflammation. This pathway also acts through inflammasomes formation 
and through caspase 1 activation, which also results in inflammation.
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as destructive role in retinal degenerations (64–67). Wurm et al. 
investigated the impact of ischemia–reperfusion injury on the 
Müller glial cells in porcine retina exposed to high intraocular 
pressure (IOP). The authors demonstrated swelling and gliosis 
through increased expression of glial fibrillary acidic protein 
(GFAP) and vimentin in Müller glia (68).
Rangasamy et  al. have shown the activation of microglia 
and macrophages in an in vivo as well as the in vitro model of 
diabetic retinopathy, another ischemia-associated condition (69). 
In  in  vitro, the authors exposed the retinal endothelial cells to 
high glucose conditions and demonstrated an increase in expres-
sion levels of macrophage marker and chemokine ligand (CCl2). 
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A similar response was observed in the rat model of diabetes 
with elevated macrophage and microglia in the retina (69). The 
activated glia after ischemic injury releases cytokines, such as 
VEGF, which assist in angiogenesis and resupply of blood (70). 
Microglia can also produce neurotrophic factors for cell survival. 
On the contrary, microglia can also release TNFα and IL1β and 
aggravate the neuronal damage (71, 72). The role of glial cells in 
the ischemic injury still needs additional investigations to target 
them as potential therapeutics.
iNFiLTRATiON OF LeUKOCYTeS: BReACH 
iN BLOOD–ReTiNA BARRieR
Ischemia–reperfusion injury also has an impact on microcircula-
tion in the tissue, which leads to infiltration of inflammatory cells 
due to increased permeability (73). The inner retinal barrier is 
known to be disrupted in many retinal diseases including ischemia 
(20, 74). Wilson et al. visualized leakage in BRB in a rabbit model 
of IOP-induced ischemia–reperfusion injury through magnetic-
resonance imaging (75). The ischemia–reperfusion injury also 
impacts the permeability by affecting the different tight-junction 
proteins that constitute the BRB, such as occludin and zona 
occludens. Muthusamy et al. in their study in IOP-induced reti-
nal ischemia model in rats have investigated the tight-junction 
proteins after injury and have shown decreased levels of occludin, 
which results in the increased vascular permeability and hence 
infiltration of leukocytes (76, 77). Tsujikawa in their study on rats 
subjected to optic nerve ligation revealed leukocyte–endothelium 
interaction through fluorescein angiography (78). Cell adhesion 
molecules, such as selectins, ICAM1, integrins, and CD11/CD18 
have also shown to play a significant role in leukocyte traffick-
ing and infiltration in ischemia (79). Stoll et  al. observed an 
increase in the levels of ICAM and selectin after focal cerebral 
ischemia, which led to permeation of T cells and macrophages 
(80). Retinal inflammation has been shown to involve adhesion of 
leukocytes to the retinal blood vessels, thus affecting the integrity 
of BRB (69). These molecules can also be exploited as therapy 
through a decrease in trafficking of immune cells. Tsujikawa 
et  al. in their another study blocked adhesion molecules using 
specific antibodies, resulting in less leukocyte accumulation 
during ischemia–reperfusion injury (81). As already discussed 
in previous sections, reperfusion of blood not only increases 
oxygen and glucose but also exacerbates the ischemic injury by 
activating inflammatory responses and promoting immune cells 
infiltration (9, 82). Lymphocytes, a sub-population of leukocytes, 
have also been associated with ischemic injury (83). Studies have 
demonstrated accumulation of T-cells (CD4+ and CD8+ cells) at 
the site of ischemic injury in the brain, where different knock-
out mice were used to investigate the role of T lymphocytes in 
cerebral ischemia (84). T lymphocytes have shown their pres-
ence at as early as 24  h after ischemic injury, which peaked at 
day 3 after the injury (85). When cerebral ischemic injury was 
induced in SCID or Rag−/− mice, which lack the T- and B-cells, 
less damage and smaller infarct volumes were observed (84). 
Involvement of T-cells, especially the IL17-producing cells, has 
also already been demonstrated in different studies in the brain 
(86, 87). In cerebral ischemia, it has been observed that the 
γδT  cells, a distinct T cell type, are the major IL17-producing 
cells (88), and the activation of these cells is the primary response 
to ischemia, which further activates matrix metalloproteinase, 
pro-inflammatory cytokines, and chemokines that are involved 
in aggravation of the ischemia–reperfusion injury. A decrease 
in infarct volume has been demonstrated in TCR-γδ knock-out 
mice subjected to ischemia (89). Shichita et al. in their study also 
highlighted a central role of γδT cells in the pathology of cerebral 
ischemia (90). These studies indicate that targeting T cells could 
be a novel therapeutic strategy for constraining inflammation 
during ischemia–reperfusion injury. Apart from these studies, 
investigations are also required to elucidate the role of T cells-
mediated immune modulation during retinal ischemia. Figure 3 
gives a brief overview of leukocyte trafficking due to breach in 
blood–retina barrier after ischemic injury to retina, along with 
the proposed mechanism about how different subtypes of T cells 
are involved in ischemia, such as CD4+ T regulatory cells that 
release anti-inflammatory TGFβ, IL10 (91), and γδT cells that 
produce IL17 through IL23 stimulation (92), along with the 
production of IL8 and VEGF from different T-cell subtypes (93).
PROTeCTOR OR PROMOTeR: 
ReGULATORY T CeLLS
Balance of immune responses is essential not only to clear the 
pathogens but also to control unwanted immune response. 
Regulatory T cells (Tregs) are the cells which were first identified 
in the mid-1990s as the cells that control the immune responses 
through feedback mechanisms (94, 95). These cells also protect 
the host against any self-antigens and any related auto-immune 
disease; however, later, it was identified that these cells also 
have a role to play in the suppression of infections, including 
uveoretinitis (96). The CD4+ T cells principally can be divided 
into two sub-populations, Th cells that activate immunity and 
Treg cells that keep a check on the Th cells activity. Treg cells are 
more precisely identified as the CD4+ CD25+ population and are 
characterized by the presence of transcription factor, fork-head 
box protein 3 (Foxp3) (97, 98). In the case of ischemia, there 
have been studies with paradox outcomes. Liesz et  al. demon-
strated a neuroprotective role of Tregs in stroke, with less infarct 
volumes accompanied by a decrease in levels of proinflammatory 
cytokines. The authors depleted the Treg cell population and 
observed an increase in secondary damage to brain post-ischemia 
along with a higher number of infiltrating leukocytes and acti-
vated microglia (99). Treg cells also secrete anti-inflammatory 
cytokines, such as IL10 and TGFβ. On the contrary, Stubbe et al. 
in their study on brain subjected to MCAO-induced ischemia 
reported the detrimental role of Treg cells (100). Kleinschnitz 
demonstrated that Tregs promote the ischemic injury and 
impact the microvasculature in the brain. The authors tested 
the effect of injury in depletion of regulatory T cells (DEREG) 
mice, which are devoid of any Tregs and revealed less infarct 
volumes after MCAO (101). Consequently, Treg cells, on the one 
hand, can protect the brain from ischemic injury by modulating 
inflammation and increasing the expression of metallomatrix 
FiGURe 3 | Trafficking of T cells after ischemia–reperfusion and related downstream response. Different T cell populations involved in ischemia–reperfusion 
injury pathogenesis. These T cells infiltrate upon breach of blood-retina barrier due to ischemia injury and different populations stimulate varied downstream signaling 
through cytokine/chemokine mediators (broken lines denotes the paradox outcomes).
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proteases; on the other hand, these cells can also aggravate the 
ischemic insult by disturbing the microvasculature and hindering 
functional recovery (102).
Retina-specific Treg cells are produced in response to antigens 
found in the retina. These can either be natural Tregs, which are 
generated against retinal antigens expressed in the thymus, or 
these can be generated independently of thymus from mature 
peripheral T cells based on exposure to antigens (103). In the 
retina, this cell population has been associated with uveoretinitis, 
where an increased number of CD4+CD25+ Tregs was detected 
in spleen and eye (104). More studies are required to investigate 
the role of Tregs in the retina and to translate the findings from 
cerebral ischemia to the retinal ischemia.
MOLeCULAR TRiGGeR: iNFLAMMATORY 
CYTOKiNeS
Cytokines are the molecules released by immune cells after 
an injury, which can be either anti-inflammatory or proin-
flammatory in nature. Ischemic injury too is associated with 
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inflammation and release of cytokines. The cytokines induce the 
migration of leukocytes in the ischemic tissue, which in turn 
release more cytokines and exacerbate the ischemic injury (105). 
Both Th1- and Th2-based immune response have been linked 
with specific proinflammatory cytokine signaling observed in 
retinal damage. Tumor necrosis factor α (TNF-α) is a proin-
flammatory cytokine, produced by microglia and leukocytes as 
an early response toward ischemia–reperfusion. The levels of 
TNFα were found to be upregulated in porcine retina 5–12  h 
after ischemia–reperfusion (106). In another model of retinal 
ischemia produced by an increase in IOP, upregulation in levels 
of TNF-α as well as its receptors, TNFR1 and TNFR2, was 
noted as early as 6 h after the reperfusion (107). The increase in 
TNF-α levels has also been reported by Yoshida et al. in ischemic 
retina. The expression was found to be localized in macrophages 
and microglia (108). TNF-α expression further increases the 
levels of other cytokines, such as IL-8 and VEGF (108, 109). 
IL17 and IFNγ mRNA levels were also found to be elevated 
in brain tissue and peripheral blood of permanent MCAO 
rat models (110). IL17 production has also been identified in 
human stroke patients (111). IL23 knock-out mice demonstrated 
smaller infarct volumes (90). IL23 mediates production of IL17 
through γδT cells (112). IL6, another Th2 response-related 
proinflammatory cytokine was detected after reperfusion in 
high IOP-induced retinal injury in rats (113). Hangai et  al. 
demonstrated many fold increase in IL1α and β levels up to 
12 h after ischemia induced by optic nerve ligation in rats (114). 
These inflammatory cytokines can also be targeted as therapy 
for ischemia–reperfusion injury. Berger et  al. demonstrated 
improvement in retinal function on treatment with TNFα 
antibody in high IOP rat model of ischemia–reperfusion (115). 
Studies have demonstrated protective role of anti-inflammatory 
interventions in ischemic injury models induced by high IOP as 
well as related retinal degenerations, such as diabetic retinopathy 
in rats (116–118).
CeLLULAR STReSS ReSPONSeS 
AND iMMUNe ReGULATiONS 
DURiNG iSCHeMiA
The cellular stress response is the homeostatic mechanism, which 
enables cells to adapt to various stress cues such as ischemia. 
Cell senses varieties of stress conditions via different sensors 
such as general control non-derepressible 2 (GCN2), which is 
activated during amino acid deprivation, heme-regulated inhibi-
tor kinase (HRI), senses heme deficiency, protein kinase RNA 
(PKR)-like endoplasmic reticulum (ER) kinase (PERK), and gets 
activated during viral infections. During stress condition, these 
sensors get phosphorylated, which further phosphorylate the 
eukaryotic initiation factor (eIF2α), resulting in the attenuation 
of active polysome formation and global protein synthesis. The 
untranslated mRNA recruits different RNA-binding proteins 
(RBPs), which together form a structure known as “riboclus-
ters.” These clusters dictate the fate of the mRNA transcripts 
(119, 120). Riboclusters formed under stress environment are 
also known to regulate the balance between inflammatory and 
anti-inflammatory cytokines through different pathways (119). 
ER is the primary organelle that is responsible for synthesis, 
folding, and trafficking of proteins. ER also participates in the 
detection of any metabolic changes to the cell through different 
cellular sensors, such as PERK, IRE1, and ATF6. Any disturbance 
in the normal physiology can lead to ER stress and hence 
activate these cellular sensors and associated stress response 
pathways in the form of unfolded protein response (UPR). 
These stress detectors are inactive under normal condition by 
glucose-regulated protein (GRP78), also known as BiP. Excessive 
stress removes the GRP78 from the sensors and makes them 
available for downstream response pathway. The UPR pathway 
responds to this stress by halting the protein translation and 
removing the misfolded proteins that have accumulated through 
chaperones. Prolonged stress can result in inflammation and 
related damage and ultimately, apoptosis, if the cell homeostasis 
is not regained (121, 122). ER stress has been implicated in vari-
ous neurodegenerative and vascular diseases including different 
retinal degeneration diseases, Stargardt’s, age-related macular 
degeneration, and retinitis pigmentosa (123). Doh et  al. have 
related ER stress with glaucoma, where high IOP stimulated 
the expression of BiP, CHOP, and phosphor-PERK along with 
ganglion cell death (124).
Prolonged stress including nutrition deprivation could also 
result in activation of homeostatic processes such as autophagy 
(125). Autophagy is a conserved defense mechanism that 
regulates protein turn-over as a normal phenomenon but is 
found to be upregulated in response to stress. Autophagy plays 
a crucial role in regulating immune responses including T-cell 
response. Coronary artery occlusion has shown to result in the 
increased levels of LC3-II conversion, a well-established marker 
for autophagy (126, 127). Different studies have investigated the 
role of autophagy in animal models of ischemic injury in the 
retina. Piras et al. demonstrated autophagy 24 h after in a retinal 
ischemia model induced by increasing the IOP (128). A similar 
outcome has been observed by Wei et al. with the accumulation 
of autophagosomes and high levels of LC3-II in RGCs, 6 h after 
the injury (129). The knowledge about cellular stress sensors and 
response pathways pertaining to retinal degeneration is still at an 
initial stage, which demands further investigations to bring out 
target therapies.
SUMMARY
Ischemia-induced retinal injury is associated with many diseases 
such as diabetic retinopathy and glaucoma, which result in 
vision impairment and blindness. With no available cure so far 
for retinal ischemia, it has become pertinent to identify potential 
targets for designing therapies. Immune modulation is one aspect 
that could be a potential therapeutic target for the ischemic 
injury. Furthermore, a better understanding about cellular stress 
responses can also help in future, to design better interventions 
for retinal ischemia–reperfusion injuries. All together, it has to 
be kept in consideration that since ischemia is a consequence 
of synergistic effects of different cell types and mechanisms; 
therefore, targeting a single cell or molecule will not reveal any 
progressive therapeutic strategy. Moreover, since ischemia is a 
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dynamic injury, it is crucial to investigate time-dependent inflam-
matory responses involved so as to keep the timing for therapy in 
consideration with minimal damage.
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